Bob W. van Oosten

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2

Bob W. van Oosten, Frederik Barkhof, L. Truyen et al. · Neurology · 1996 · 733 citations

Life Sciences, Immunology, Neurology +17

Accumulation of hypointense lesions ("black holes") on T ₁ spin-echo MRI correlates with disease progression in multiple sclerosis

L. Truyen, J.H.T.M. van Waesberghe, M.A.A. van Walderveen et al. · Neurology · 1996 · 465 citations

Medicine, Neurology, Radiology +17

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial

Bob W. van Oosten, Mitchell K.P. Lai, Suzanne Hodgkinson et al. · Neurology · 1997 · 268 citations

Life Sciences, Immunology, Neurology +15

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

Anette H.H. van Boxel-Dezaire, Sabine Hoff, Bob W. van Oosten et al. · Annals of Neurology · 1999 · 267 citations

Life Sciences, Immunology, Pathobiology +17